Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Idiopathic Pulmonary Fibrosis (IPF) now has two licensed treatments available. Pirfenidone
was the first drug to be licensed and approved for use, followed by nintedanib. We set out …

Abstract Background: RECAP (NCT00662038) was an open-label extension study in
patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of …

BACKGROUND: Conducting an adequately powered survival study in idiopathic pulmonary
fibrosis (IPF) is challenging due to the rare nature of the disease and the need for extended …

Introduction Pirfenidone, an antifibrotic drug, slows-down the disease progression in
idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Idiopathic pulmonary fibrosis (IPF) is a chronic, irreversible, progressively destructive lung
disease that culminates in respiratory failure and death. Randomised controlled trials have …

Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is
approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) …

The landscape of idiopathic pulmonary fibrosis (IPF) has changed. The significant progress
regarding our knowledge on the pathogenesis of the disease together with the experience …